Tag: CNS product candidate
July 10, 2017
VistaGen Seeks to Advanced the Development of AV-101
VistaGen Therapeutics appointed Dr. Mark Wallace to its clinical advisory board to advanced the company's non-opioid treatment. April 27, 2017
VistaGen's AV-101 Featured in Peer-Reviewed Publication
VistaGen Therapeutics announced the publication of a nonclinical study on the effects of AV-101, the company's central nervous system disorder... March 29, 2017